Role of recombinant factor 7 in PPH: a new weapon in obstetrician’s armamentarium
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243602Keywords:
DIC, PPH, Recombinant factor VIIaAbstract
Background: Post-partum hemorrhage (PPH) is a life-threatening obstetric complication and the leading cause of maternal death. It is currently managed mainly through surgical interventions with simultaneous transfusion of blood and blood-derived. However, in critical conditions the achievement of hemostasis and reversal of coagulopathy becomes more difficult. Here we are sharing an experience of 41 cases of severe PPH with different causes of PPH treated with new noninvasive advancement, recombinant factor 7 in PPH.
Methods: This was a prospective observational study at Pannadhaya Rajkiya Mahila Chikitsalya Udaipur (Rajasthan) from May 2023 to December 2023. Here we are sharing an experience of 41 cases of severe PPH with different causes of PPH treated with new noninvasive advancement, recombinant factor 7 in PPH.
Results: Out of 41 cases clinical response to rFVIIa (defined as bleeding decreased or stopped at 1 hour post administration) was seen in 26/41 (63%) patients. There was mortality of 5 patients. So, the total mortality rate was 12% in our study.
Conclusions: Obstetric hemorrhage can progress rapidly and is strongly associated with the development of disseminated intravascular coagulation (DIC). Delayed correction of DIC is associated with a significant increase in morbidity and mortality. Rapid correction of coagulopathy with ongoing regular monitoring of coagulation status is often difficult to coordinate in the setting of acute life-threatening obstetric hemorrhage. Factor VII helps in haemostasis.
Metrics
References
World Health Organization. WHO postpartum haemorrhage (PPH) summit. World Health Organization. 2022. Available from: https://www.who.int/publications/m/item/who-postpartum-haemorrhage-(pph)-summit. Accessed on 28 April 2022.
Wormer KC, Jamil RT, Bryant SB. Acute postpartum hemorrhage. StatPearls. 2023.
Escobar MF, Nassar AH, Theron G, Barnea ER, Nicholson W, Ramasauskaite D, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynecol Obstet. 2022;157:3-50.
Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG. 2007;114(1):8-15.
Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL, Targher G, et al. The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynecol. 2010;53(1):219-27.
Hossain N, Shamsi T, Haider S, Soomro N, Khan NH, Umer Memon G, et al. Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand. 2007;86(10):1200-6.
Magon N, Babu KM, Kapur K, Chopra S, Joneja GS. Recombinant activated factor VII in post partum haemorrhage. Niger Med J. 2013;54(5):289-94.
Lavigne‐Lissalde G, Aya AG, Mercier FJ, Roger‐Christoph S, Chauleur C, Morau E, et al. Recombinant human FVIIa for reducing the need for invasive second‐line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thrombos Haemost. 2015;13(4):520-9.
Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med. 2008;59(1):29-41.
Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Rev. 2015;29:S4-8.
Bomken C, Mathai S, Biss T, Loughney A, Hanley J. Recombinant activated factor VII (rFVIIa) in the management of major obstetric haemorrhage: a case series and a proposed guideline for use. Obstet Gynecol Int. 2009;2009:364843.
Ahonen J, Jokela R, Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum hemorrhage. Acta Anaesthesiol Scand. 2007;51:929-36
O’Connell NM, Perry DJ. The use of recombinant factor VIIa in surgical bleeding in nonhemophiliac patients. Transfus Altern Transfus Med. 2003;5:31-6.
Moscardó F, Pérez F, De La Rubia J, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Hematol. 2001;114:174-6.
Searle E, Pavord S, Alfirevic Z. Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):1075-88.
Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the northern European registry 2000-2004. Obstet Gynecol. 2007;110(6):1270-8.
Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric hemorrhage. Int J Obstet Anesth. 2007;16:40-9.
Barillari G, Frigo MG, Casarotto M, Farnia A, Massè B, Wetzl R, et al. Use of recombinant activated factor VII in severe post-partum haemorrhage: Data from the Italian registry. Thromb Res. 2009;124:e41-7.
